Half-boosted Fosamprenavir — Competitive Intelligence Brief

Half-boosted Fosamprenavir (Half-boosted Fosamprenavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Half-boosted Fosamprenavir (Half-boosted Fosamprenavir) — GlaxoSmithKline. Half-boosted fosamprenavir is an HIV protease inhibitor that blocks viral protease enzyme activity with reduced ritonavir boosting compared to standard fosamprenavir formulations.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Half-boosted Fosamprenavir TARGET	Half-boosted Fosamprenavir	GlaxoSmithKline	phase 3	HIV protease inhibitor	HIV protease
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Continue Ritonavir-boosted PI+Rosuvastatin	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
LPV/r	LPV/r	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Protease inhibitor (PI) combination	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class